Research programme: mental disorder therapeutics - Integrative Research Laboratories

Drug Profile

Research programme: mental disorder therapeutics - Integrative Research Laboratories

Alternative Names: IRL 626; P 001

Latest Information Update: 02 Mar 2016

Price : $50

At a glance

  • Originator Integrative Research Laboratories
  • Class
  • Mechanism of Action Central nervous system stimulants; Dopamine D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Schizophrenia
  • Research Attention-deficit hyperactivity disorder

Most Recent Events

  • 01 Mar 2016 IRL 626 is available for licensing as of 01 Mar 2016. http://www.irlab.se/programmes/
  • 01 Mar 2016 Early research in Attention-deficit hyperactivity disorder in Sweden (unspecified route) before March 2016
  • 01 Mar 2016 Preclinical trials in Schizophrenia in Sweden (unspecified route) before March 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top